METTL16, through the HIF-2α-PMEPA1-autophagy axis, significantly inhibits the proliferation of bladder cancer (BLCA) cells in vitro and in vivo via m6A modification, increasing the sensitivity of these cells to cisplatin. This evidence concerns the gene METTL16 and bladder transitional cell carcinoma.